The studies, entitled, "Recognition of Ii-Key/MHC Class II Epitope Hybrids Derived from Proinsulin and GAD Peptides by T Cells in Type 1 Diabetes," according to a company press release, and are "applicable to the early diagnosis, and possibly treatment of, Type 1 diabetes."
The results appear in the April issue of the international peer-reviewed journal Hormone and Metabolism Research.
The real short term potential market-moving event for Generex would be word as to whether or not the FDA will allow results from the Phase III Oral-lyn trial to be used as a basis for approval, given that the trial did not enroll the originally intended number of patients.
Additionally, a vote on a reverse split is due to take place, and Generex has outlined the strategy moving forward in the event an RS does - or does not - take place.
GNBT has been idle for some time, but come vote time, things could get interesting.
Disclosure: Long GNBT.
ONTY: Shares of Oncothyreon have since retreated after rising to over five dollars recently, on news that the company has conducted a stock sale that raised $40 million.
According to the company press release, the funds will be used "to fund the development of PX-866,
Stimuvax is a cancer immunotherapy treatment currently being tested in a Phase III trial for non-small cell lung cancer and is partnered with Merck KGaA.
Oncothyreon remains a candidate to become 'The Next Dendreon', in terms of hitting the market with a splash by having a cancer vaccine approved.
Keep in mind, however, that most cancer vaccines fail in the pursuit of approval, so although the rewards look good - don't ignore the inherent risk.
Disclosure: Long ONTY.
DNDN: Dendreon (DNDN) continues to chip away at the lofty expectations predicted by the company and analysts for this fiscal year, as first quarter revenue numbers were reported as coming in at just over $28 million.
Shares of DNDN had been on a steady rise throughout the first quarter, as higher earnings numbers were expected once the FDA approved additional manufacturing capacity at Dendreon's New Jersey Provenge manufacturing facility.
The true benefits of the additional manufacturing capacity, however, were not expected to be felt until the second quarter of this year as the work stations are being brought online in a phased approach.
Dendreon issued evidence to that fact by announcing April revenue of $15 million along with the first quarter numbers. Already, just one month into the second quarter, revenue has exceeded half that of the first quarter, offering a glimpse that full 2011 revenue expectations of $350-$400 million may be achievable.
CLICK HERE FOR FULL ARTICLE